secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARDELYX, INC. (ARDX)
CIK:        0001437402
Form:       8-K
Filed at:   2026-04-30T23:59:59+00:00
Accession:  0001437402-26-000021
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ardelyx Q1 revenue $93.4M (+38% YoY); IBSRELA revenue $70.1M (+58% YoY)
-----------------------------------------------------------------------

- Net loss $37.6M ($0.15/sh) vs $41.1M ($0.17/sh) Q1 2025; share-based comp $14.2M.
- Cash & investments $238.1M as of Mar 31, 2026; reiterated FY 2026 IBSRELA guidance $410-430M.
- IBSRELA Phase 3 CIC trial (ACCEL) enrolling; topline data expected H2 2027.
- Appointed Rajani Dinavahi, M.D. as CMO and Felecia Ettenberg, Esq. as CLO in April.
- Refinanced debt with SLR Investment Corp for better terms; Morgan Stanley advised.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1437402/000143740226000021/0001437402-26-000021-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1437402/000143740226000021/ardx-20260430.htm
  HTML page:      https://secwatch.observer/filing/0001437402-26-000021

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer